key: cord-0733797-78x4bkqd
authors: Medranda, Giorgio A.; Yerasi, Charan; Case, Brian C.; Forrestal, Brian J.; Chezar-Azerrad, Chava; Wermers, Jason P.; Waksman, Ron
title: Review of PCR e-Course 2020 late-breaking clinical trials
date: 2020-07-23
journal: Cardiovasc Revasc Med
DOI: 10.1016/j.carrev.2020.07.022
sha: c820c7e16c3c30f92e46258fe43eb586f1b8e574
doc_id: 733797
cord_uid: 78x4bkqd

• Paris Course of Revascularisation has shared cardiovascular expertise since 1989. • EuroPCR was canceled because of the COVID-19 pandemic. • PCR e-Course was held in place of EuroPCR. • We review highlights of late-breaking clinical trials from PCR e-Course.

Since 1989, the Paris Course of Revascularisation (PCR) has shared expertise and experience in cardiovascular medicine with healthcare professionals around the world. This year, EuroPCR was canceled because of the COVID-19 pandemic. In its place, the PCR e-Course was held to offer the latest cardiovascular science and an opportunity for interventional cardiologists to interact with, and learn from, experts and peers around the world.

J o u r n a l P r e -p r o o f indicated target lesion revascularization (TLR). The primary imaging/efficacy endpoints for those patients undergoing imaging follow-up was the change in mean in-device area and mean lumen area at 9 or 12 months compared to post-procedure as measured by intravascular ultrasound (IVUS). The co-primary imaging/efficacy endpoint for those patients undergoing imaging follow-up was late lumen loss as measured by quantitative coronary angiography and IVUS at 9 or 12 months.

The results by Stefan Verheye, MD, PhD, of ZNA Middleheim Antwerp Cardiovascular Center, Belgium, and co-investigators demonstrated no TLF through 6 months and two patients (4%) experiencing TLF (both died of cardiac causes) through 12 months. Verheye noted that there was no TLR through 1 year. Patients who underwent IVUS also showed positive adaptive remodeling to maintain lumen area (post-procedure, 7.39 mm 2 ; at 9 and 12 months, 7.36 mm 2 ; with 0% change from post-procedure, p=0.594). There were changes in mean vessel area (postprocedure, 14.10 mm 2 ; at 9 and 12 months, 14.54 mm 2 ; with 3% change from post-procedure, p=0.017) and mean bioadaptor area (post-procedure 7.39 mm 2 ; at 9 and 12 months, 7.74 mm 2 ; with 5% change from post-procedure, p=0.0005).

The increases in vessel and device area allow the vessel to maintain the lumen diameter and preserve good blood flow over time. This is important because DES have high major adverse cardiac event (MACE) rates beyond 1-year, at a rate of 2% to 3% without plateau. The study showed that iFR resulted in more patients having revascularization deferred (iFR 50% vs. FFR 45%, p<0.01). However, the risk of death, non-fatal myocardial infarction (MI) and unplanned revascularization over 2 years was no different in the FFR or iFR group (iFR 7.43% vs. FFR 7.4%, p=0.94). Individual components of death, non-fatal MI, and unplanned revascularization were also comparable between the groups. The study also demonstrated that FFR led to more revascularization procedures, particularly in patients younger than 60 years of age; these younger patients had 12% more revascularizations when FFR was used.

The study suggests similar safety of iFR and FFR in deferring revascularization in the midterm and reveals a strong interaction between age and FFR-based deferral, potentially secondary to a varying age-related hyperemic response to adenosine.

The DEFINE FLAIR and IFR SWEDEHEART studies were funded through unrestricted grants from Philips-Volcano. This study was limited by the retrospective nature of the study with inherent selection bias, as seen by the numerous differences between both treatment groups. Additionally, there was a large proportion of patients lost to follow-up whose outcomes could not be accurately assessed.

The author's conclude that CABG may be the gold standard for patients with MVD and CTOs; however, in certain clinical settings, PCI may be an appropriate alternative to achieve revascularization. The analysis demonstrated that of the 72 patients in the original sham-control group, 31 had crossed over to undergo renal denervation after 12 months of uncontrolled blood pressure. These crossover patients had a mean age of 54 years, 39% were women, 77% were white, 13% were Black, they had an average body mass index of 28.1 kg/m 2 , and an estimated glomerular filtration rate of 80 mL/min/1.73m 2 . At time of crossover, they had a mean blood pressure of 145/90 mmHg and were on an average of 1.2 antihypertensive medications.

All of these patients had successful denervation, with no adverse events. Their postdenervation daytime ambulatory systolic blood pressure decreased by 11.2 mmHg at 2 months and by 12.2 mmHg at 6 months. The percentage of patients who saw their daytime ambulatory systolic blood pressure drop by at least 5 mmHgwithout increasing medicationswas 71% at 2 months and 68% at 6 months.

Although crossover subjects and physicians were unblinded, making them possibly biased as far as both medication or behavioral effects, or both, the results of the new analysis remained similar to those found in the original study.

The RADIANCE-HTN SOLO trial was sponsored by ReCor Medical Inc.

Uncaging" Platform for Coronary Artery Revascularization: 12-Month Clinical and Imaging Results

Two-stent vs. provisional for bifurcation PCI: the DEFINITION II trial

Two-year safety of revascularisation deferral based on iFR or FFR

Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in Patients with Chronic Total Occlusion and Multivessel Disease

Routine Revascularization versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials

Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials

(49)/Kirtane_Ajay_20200626_140 0_Main_Arena_Channel